KPB Association Seminar on the 28th
Obesity, Artificial Intelligence (AI), and China Take Center Stage

This year, the key themes in the global pharmaceutical and bio industry are being distilled down to obesity treatments, artificial intelligence (AI), and China. While the domestic pharmaceutical and bio sector is expected to continue its growth trajectory from last year, experts advise that companies must craft sophisticated strategies for technology transfer and clinical trials to capitalize on the 'golden time' of the next one to two years.


On January 28, the Korea Pharmaceutical and Bio Association held a seminar at its headquarters in Seocho-gu, Seoul, under the theme "The Direction of the Global Pharmaceutical and Bio Industry in 2026 and Opportunities for K-Bio in an Era of Uncertainty," where this year's industry trends and corporate response strategies were reviewed.


"Market on Alert for Oral Obesity Drug Clinical Results"

Heo Hyemin, Head of the Research Center at Kiwoom Securities, said, "Last year, domestic companies achieved record-high results, and the number of deals with global big pharma increased from the usual two to three per year to seven to eight last year. Since some anticipated deals from last year have carried over, whether the scale of technology transfers in the first half of this year will surpass last year's will be a key inflection point for the market."


A panel discussion is underway at the seminar titled "The Direction of the Global Pharmaceutical and Bio Industry in 2026 and Opportunities for K-Bio in an Era of Uncertainty," held on the 28th at the Korea Pharmaceutical and Bio Association in Seocho-gu, Seoul. Photo by Lee Sungmin

A panel discussion is underway at the seminar titled "The Direction of the Global Pharmaceutical and Bio Industry in 2026 and Opportunities for K-Bio in an Era of Uncertainty," held on the 28th at the Korea Pharmaceutical and Bio Association in Seocho-gu, Seoul. Photo by Lee Sungmin

View original image


This year, the hot spot in the new drug market remains obesity treatments. Heo explained, "The top two players (Eli Lilly and Novo Nordisk) are competing over oral formulations, while the third and fourth (Amgen and Pfizer) are focusing on once-monthly formulations. In particular, the market will place even greater pressure on clinical data this year." She added, "Clinical data for once-monthly formulations from the third and fourth tier companies are expected this year, and depending on the results, the landscape for technology licensing could change."


Uncertainty stemming from U.S. regulations is now considered to be resolved. Heo pointed out that, unlike in the past, domestic bio stocks did not experience extreme volatility even when issues like tariffs and drug pricing were highlighted, saying, "Now is the time to focus on corporate fundamentals."


She continued, "Although this is the first year of the Inflation Reduction Act's (IRA) drug price cuts, areas where prices have already dropped due to patent expirations and the spread of biosimilars may experience only limited additional impact. There have also been cases where the price of new obesity drugs was reduced by 30-35% due to public insurance coverage, despite being new drugs. With injectable prices already lowered, the key point to watch this year is how much oral prescriptions will increase."


"AI Drug Development: Data from '60% of the Population' in Asia Is the Game Changer"

AI is emerging not just as a tool for drug development, but as a foundation that determines competitive advantage in the pharmaceutical and bio sector. Kim Irang, CEO of Oncocross, stated, "To survive against big tech, we must fill in areas they lack or do not address. Global pharmaceutical companies mainly possess clinical data from white populations, but Asians make up 60% of the world's population, and East Asians alone account for over 20%."


She emphasized, "It is difficult to beat big tech using only public data. The key is to create and accumulate unique data that we can secure." Won Jongheon, Head of Division at LG Chem, also said, "AI can be utilized throughout the entire cycle, from drug discovery to clinical trials and commercialization. The breadth and execution of applicable areas will determine competitiveness."


China was again identified as the most important variable this year. Heo commented, "China must be closely watched again this year. The perspective of overseas stakeholders toward the Asia-Pacific region, including Korea and China, is changing, which has increased our negotiating power." She added, "A friend from China told me that for the past 15 years, Western countries were the benchmark for technology transfer trends, but last year, for the first time, China became the benchmark. Now, the real beginning is here."


Cho Youngguk, CEO of Global Venture Network, said, "Now, we are in a position where we must quickly catch up with China. Last year, it is estimated that 40% of global technology transfer contracts originated from China."



However, on-site opinions emphasized that China should not be viewed solely as a competitor, but also as a potential partner for collaboration. Won pointed out, "China’s speed in new drug development is extremely fast, with the process from clinical entry to NDA (New Drug Application) approval taking just three to four years. It is very difficult for domestic companies to compete head-to-head." He suggested, "Instead, collaboration could become an even more important topic. If domestic companies adopt a strategy to quickly secure proof of concept (PoC) in early clinical development locally in China, they can fully compete in terms of speed during the one to two-year golden time."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing